Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company's lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company's technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
Lexaria Bioscience Corp.
CNSX:LXX ISIN:US52886N3070
News
Lexaria Bioscience Corp. (OTCMKTS:LXRP) (CSE:LXX) is pleased to announce it has received a Notice of Acceptance from the Australian Patent Office that Lexaria's Australian patent application 2015274698 has been accepted with a patent issuance date expected in June, 2017.
###
1,294 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 3) (Last 30 Days: 15) (Since Published: 1294)